Resmetirom Opens Path for New Liver Fibrosis Therapies The North America Metabolic Dysfunction–Associated Steatohepatitis (MASH) Treatment Market is witnessing exponential growth, rising from USD 3.70 billion in 2024 to an anticipated USD 17.15 billion by 2033, at a strong compound annual growth rate (CAGR) of 19.3% from 2025 to 2033.
This dynamic expansion is fueled by the increasing prevalence of obesity, Type 2 diabetes, aging population,...
0 Shares
8 Views
0 Reviews